Non-viral vectors for gene-based therapy

被引：2519
作者：
Yin, Hao [1 ]
Kanasty, Rosemary L. [1 ,2 ]
Eltoukhy, Ahmed A. [1 ]
Vegas, Arturo J. [1 ,3 ]
Dorkin, J. Robert [1 ,4 ]
Anderson, Daniel G. [1 ,2 ,3 ,5 ,6 ]
机构：
[1] MIT, David H Koch Inst Integrat Canc Res, Cambridge, MA 02142 USA
[2] MIT, Dept Chem Engn, Cambridge, MA 02142 USA
[3] Childrens Hosp, Dept Anesthesiol, Boston, MA 02115 USA
[4] MIT, Dept Biol, Cambridge, MA 02142 USA
[5] MIT, Harvard Mit Div Hlth Sci & Technol, Cambridge, MA 02139 USA
[6] MIT, Inst Med Engn & Sci, Cambridge, MA 02142 USA
来源：
NATURE REVIEWS GENETICS | 2014年 / 15卷 / 08期
基金：
美国国家科学基金会; 美国国家卫生研究院;
关键词：
IN-VIVO DELIVERY; PLASMID-LIPID PARTICLES; MODIFIED MESSENGER-RNA; TRANSGENE EXPRESSION; TARGETED DELIVERY; SLEEPING-BEAUTY; VIRAL VECTORS; ADMINISTERED SIRNA; NONHUMAN-PRIMATES; SYSTEMIC DELIVERY;
D O I：
10.1038/nrg3763
中图分类号：
Q3 [遗传学];
学科分类号：
071007 ; 090102 ;
摘要：
Gene-based therapy is the intentional modulation of gene expression in specific cells to treat pathological conditions. This modulation is accomplished by introducing exogenous nucleic acids such as DNA, mRNA, small interfering RNA (siRNA), microRNA (miRNA) or antisense oligonucleotides. Given the large size and the negative charge of these macromolecules, their delivery is typically mediated by carriers or vectors. In this Review, we introduce the biological barriers to gene delivery in vivo and discuss recent advances in material sciences, nanotechnology and nucleic acid chemistry that have yielded promising non-viral delivery systems, some of which are currently undergoing testing in clinical trials. The diversity of these systems highlights the recent progress of gene-based therapy using non-viral approaches.
引用
收藏
页码：541 / 555
页数：15
相关论文
共 159 条
  • [1] Phenotypic heterogeneity of the endothelium I. Structure, function, and mechanisms
    Aird, William C.
    [J]. CIRCULATION RESEARCH, 2007, 100 (02) : 158 - 173
  • [2] Targeted Delivery of RNAi Therapeutics With Endogenous and Exogenous Ligand-Based Mechanisms
    Akinc, Akin
    Querbes, William
    De, Soma
    Qin, June
    Frank-Kamenetsky, Maria
    Jayaprakash, K. Narayanannair
    Jayaraman, Muthusamy
    Rajeev, Kallanthottathil G.
    Cantley, William L.
    Dorkin, J. Robert
    Butler, James S.
    Qin, LiuLiang
    Racie, Timothy
    Sprague, Andrew
    Fava, Eugenio
    Zeigerer, Anja
    Hope, Michael J.
    Zerial, Marino
    Sah, Dinah W. Y.
    Fitzgerald, Kevin
    Tracy, Mark A.
    Manoharan, Muthiah
    Koteliansky, Victor
    de Fougerolles, Antonin
    Maier, Martin A.
    [J]. MOLECULAR THERAPY, 2010, 18 (07) : 1357 - 1364
  • [3] Development of Lipidoid-siRNA Formulations for Systemic Delivery to the Liver
    Akinc, Akin
    Goldberg, Michael
    Qin, June
    Dorkin, J. Robert
    Gamba-Vitalo, Christina
    Maier, Martin
    Jayaprakash, K. Narayanannair
    Jayaraman, Muthusamy
    Rajeev, Kallanthottathil G.
    Manoharan, Muthiah
    Koteliansky, Victor
    Roehl, Ingo
    Leshchiner, Elizaveta S.
    Langer, Robert
    Anderson, Daniel G.
    [J]. MOLECULAR THERAPY, 2009, 17 (05) : 872 - 879
  • [4] Multiparametric approach for the evaluation of lipid nanoparticles for siRNA delivery
    Alabi, Christopher A.
    Love, Kevin T.
    Sahay, Gaurav
    Yin, Hao
    Luly, Kathryn M.
    Langer, Robert
    Anderson, Daniel G.
    [J]. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2013, 110 (32) : 12881 - 12886
  • [5] Atu027, a Liposomal Small Interfering RNA Formulation Targeting Protein Kinase N3, Inhibits Cancer Progression
    Aleku, Manuela
    Schulz, Petra
    Keil, Oliver
    Santel, Ansgar
    Schaeper, Ute
    Dieckhoff, Britta
    Janke, Oliver
    Endruschat, Jens
    Durieux, Birgit
    Roeder, Nadine
    Loeffler, Kathrin
    Lange, Christian
    Fechtner, Melanie
    Moepert, Kristin
    Fisch, Gerald
    Dames, Sibylle
    Arnold, Wolfgang
    Jochims, Karin
    Giese, Klaus
    Wiedenmann, Bertram
    Scholz, Arne
    Kaufmann, Joerg
    [J]. CANCER RESEARCH, 2008, 68 (23) : 9788 - 9798
  • [6] Factors affecting the clearance and biodistribution of polymeric nanoparticles
    Alexis, Frank
    Pridgen, Eric
    Molnar, Linda K.
    Farokhzad, Omid C.
    [J]. MOLECULAR PHARMACEUTICS, 2008, 5 (04) : 505 - 515
  • [7] Stabilized plasmid-lipid particles containing PEG-diacylglycerols exhibit extended circulation lifetimes and tumor selective gene expression
    Ambegia, E
    Ansell, S
    Cullis, P
    Heyes, J
    Palmer, L
    MacLachlan, I
    [J]. BIOCHIMICA ET BIOPHYSICA ACTA-BIOMEMBRANES, 2005, 1669 (02): : 155 - 163
  • [8] Nucleoside modifications in RNA limit activation of 2'-5'-oligoadenylate synthetase and increase resistance to cleavage by RNase L
    Anderson, Bart R.
    Muramatsu, Hiromi
    Jha, Babal K.
    Silverman, Robert H.
    Weissman, Drew
    Kariko, Katalin
    [J]. NUCLEIC ACIDS RESEARCH, 2011, 39 (21) : 9329 - 9338
  • [9] Persistent episomal transgene expression in liver following delivery of a scaffold/matrix attachment region containing non-viral vector
    Argyros, O.
    Wong, S. P.
    Niceta, M.
    Waddington, S. N.
    Howe, S. J.
    Coutelle, C.
    Miller, A. D.
    Harbottle, R. P.
    [J]. GENE THERAPY, 2008, 15 (24) : 1593 - 1605
  • [10] The Sleeping Beauty transposon system: a non-viral vector for gene therapy
    Aronovich, Elena L.
    McIvor, R. Scott
    Hackett, Perry B.
    [J]. HUMAN MOLECULAR GENETICS, 2011, 20 : R14 - R20
12345678910